The  ||| S:0 E:4 ||| DT
Way  ||| S:4 E:8 ||| NNP
Forward ||| S:8 E:15 ||| NNP
:  ||| S:15 E:17 ||| :
Practical  ||| S:17 E:27 ||| NNP
Clinical  ||| S:27 E:36 ||| NNP
Considerations  ||| S:36 E:51 ||| NNP
for  ||| S:51 E:55 ||| IN
the  ||| S:55 E:59 ||| DT
Use  ||| S:59 E:63 ||| NN
of  ||| S:63 E:66 ||| IN
Canakinumab  ||| S:66 E:78 ||| NNP
in  ||| S:78 E:81 ||| IN
Patients  ||| S:81 E:90 ||| NNS
With  ||| S:90 E:95 ||| IN
Difficult-to-Treat  ||| S:95 E:114 ||| NNP
Gouty  ||| S:114 E:120 ||| NNP
Arthritis  ||| S:120 E:130 ||| NNP
Canakinumab  ||| S:130 E:142 ||| NNP
is  ||| S:142 E:145 ||| VBZ
indicated  ||| S:145 E:155 ||| VBN
for  ||| S:155 E:159 ||| IN
patients  ||| S:159 E:168 ||| NNS
with  ||| S:168 E:173 ||| IN
frequent  ||| S:173 E:182 ||| JJ
gouty  ||| S:182 E:188 ||| JJ
arthritis  ||| S:188 E:198 ||| NN
attacks  ||| S:198 E:206 ||| NNS
who  ||| S:206 E:210 ||| WP
cannot  ||| S:210 E:217 ||| RB
be  ||| S:217 E:220 ||| VB
managed  ||| S:220 E:228 ||| VBN
with  ||| S:228 E:233 ||| IN
standard-of-care  ||| S:233 E:250 ||| JJ
medication ||| S:250 E:260 ||| NN
,  ||| S:260 E:262 ||| ,
and  ||| S:262 E:266 ||| CC
should  ||| S:266 E:273 ||| MD
be  ||| S:273 E:276 ||| VB
used  ||| S:276 E:281 ||| VBN
according  ||| S:281 E:291 ||| VBG
to  ||| S:291 E:294 ||| TO
the  ||| S:294 E:298 ||| DT
labeled  ||| S:298 E:306 ||| JJ
indication ||| S:306 E:316 ||| NN
.  ||| S:316 E:318 ||| .
Given  ||| S:318 E:324 ||| VBN
its  ||| S:324 E:328 ||| PRP$
mechanism  ||| S:328 E:338 ||| NN
of  ||| S:338 E:341 ||| IN
action ||| S:341 E:347 ||| NN
,  ||| S:347 E:349 ||| ,
physicians  ||| S:349 E:360 ||| NNS
need  ||| S:360 E:365 ||| VBP
to  ||| S:365 E:368 ||| TO
be  ||| S:368 E:371 ||| VB
aware  ||| S:371 E:377 ||| JJ
of  ||| S:377 E:380 ||| IN
the  ||| S:380 E:384 ||| DT
potential  ||| S:384 E:394 ||| JJ
contraindications  ||| S:394 E:412 ||| NN
and  ||| S:412 E:416 ||| CC
precautions  ||| S:416 E:428 ||| NNS
with  ||| S:428 E:433 ||| IN
its  ||| S:433 E:437 ||| PRP$
use ||| S:437 E:440 ||| NN
.  ||| S:440 E:442 ||| .
When  ||| S:442 E:447 ||| WRB
deciding  ||| S:447 E:456 ||| VBG
as  ||| S:456 E:459 ||| RB
to  ||| S:459 E:462 ||| TO
whether  ||| S:462 E:470 ||| IN
a  ||| S:470 E:472 ||| DT
patient  ||| S:472 E:480 ||| NN
with  ||| S:480 E:485 ||| IN
gouty  ||| S:485 E:491 ||| JJ
arthritis  ||| S:491 E:501 ||| NN
is  ||| S:501 E:504 ||| VBZ
an  ||| S:504 E:507 ||| DT
appropriate  ||| S:507 E:519 ||| JJ
candidate  ||| S:519 E:529 ||| NN
for  ||| S:529 E:533 ||| IN
canakinumab  ||| S:533 E:545 ||| JJ
treatment ||| S:545 E:554 ||| NN
,  ||| S:554 E:556 ||| ,
several  ||| S:556 E:564 ||| JJ
key  ||| S:564 E:568 ||| JJ
clinical  ||| S:568 E:577 ||| JJ
considerations  ||| S:577 E:592 ||| NNS
should  ||| S:592 E:599 ||| MD
be  ||| S:599 E:602 ||| VB
kept  ||| S:602 E:607 ||| VBN
in  ||| S:607 E:610 ||| IN
mind ||| S:610 E:614 ||| NN
,  ||| S:614 E:616 ||| ,
which  ||| S:616 E:622 ||| WDT
are  ||| S:622 E:626 ||| VBP
discussed  ||| S:626 E:636 ||| VBN
herein ||| S:636 E:642 ||| NN
.  ||| S:642 E:644 ||| .
